These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29304474)

  • 1. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
    Guo Y; Hu J; Wang Y; Peng X; Min J; Wang J; Matthaiou E; Cheng Y; Sun K; Tong X; Fan Y; Zhang PJ; Kandalaft LE; Irving M; Coukos G; Li C
    Eur J Cancer; 2018 Feb; 90():111-121. PubMed ID: 29304474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.
    Li C; Wang J; Hu J; Feng Y; Hasegawa K; Peng X; Duan X; Zhao A; Mikitsh JL; Muzykantov VR; Chacko AM; Pryma DA; Dunn SM; Coukos G
    Oncotarget; 2014 Aug; 5(16):6994-7012. PubMed ID: 25051365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
    Rouleau C; Curiel M; Weber W; Smale R; Kurtzberg L; Mascarello J; Berger C; Wallar G; Bagley R; Honma N; Hasegawa K; Ishida I; Kataoka S; Thurberg BL; Mehraein K; Horten B; Miller G; Teicher BA
    Clin Cancer Res; 2008 Nov; 14(22):7223-36. PubMed ID: 19010839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.
    D'Onofrio A; Gano L; Melo R; Mendes F; Oliveira MC; Denoël T; Schaefer N; Viertl D; Fierle J; Coukos G; Dunn S; Prior JO; Paulo A
    Eur J Pharm Biopharm; 2021 Jan; 158():233-244. PubMed ID: 33271301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
    Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
    Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of TEM1/endosialin in human and murine brain tumors.
    Carson-Walter EB; Winans BN; Whiteman MC; Liu Y; Jarvela S; Haapasalo H; Tyler BM; Huso DL; Johnson MD; Walter KA
    BMC Cancer; 2009 Nov; 9():417. PubMed ID: 19948061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation and Dosimetry of [
    Cicone F; Denoël T; Gnesin S; Riggi N; Irving M; Jakka G; Schaefer N; Viertl D; Coukos G; Prior JO
    Mol Imaging Biol; 2020 Aug; 22(4):979-991. PubMed ID: 31993928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
    Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A
    Cancer Immunol Immunother; 2017 Mar; 66(3):367-378. PubMed ID: 27933426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
    Fierle JK; Brioschi M; de Tiani M; Wetterwald L; Atsaves V; Abram-Saliba J; Petrova TV; Coukos G; Dunn SM
    Cell Rep Med; 2021 Aug; 2(8):100362. PubMed ID: 34467246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.
    Zhao A; Nunez-Cruz S; Li C; Coukos G; Siegel DL; Scholler N
    J Immunol Methods; 2011 Jan; 363(2):221-32. PubMed ID: 20837020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
    Matthaiou EI; Guo Y; Barar J; Sandaltzopoulos R; Kandalaft LE; Li C; Coukos G; Omidi Y
    Bioimpacts; 2022; 12(1):65-86. PubMed ID: 35087718
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.
    Li C; Chacko AM; Hu J; Hasegawa K; Swails J; Grasso L; El-Deiry WS; Nicolaides N; Muzykantov VR; Divgi CR; Coukos G
    Cancer Biol Ther; 2014 Apr; 15(4):443-51. PubMed ID: 24553243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.
    Rouleau C; Smale R; Fu YS; Hui G; Wang F; Hutto E; Fogle R; Jones CM; Krumbholz R; Roth S; Curiel M; Ren Y; Bagley RG; Wallar G; Miller G; Schmid S; Horten B; Teicher BA
    Int J Oncol; 2011 Jul; 39(1):73-89. PubMed ID: 21537839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-targeting fusion constructs containing recombinant gelonin.
    Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
    Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration.
    Tomkowicz B; Rybinski K; Foley B; Ebel W; Kline B; Routhier E; Sass P; Nicolaides NC; Grasso L; Zhou Y
    Proc Natl Acad Sci U S A; 2007 Nov; 104(46):17965-70. PubMed ID: 17986615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
    Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W
    Theranostics; 2024; 14(1):379-391. PubMed ID: 38164138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
    Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A; Scholler N; Coukos G
    Cancer Immunol Immunother; 2018 Feb; 67(2):329-339. PubMed ID: 29313073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.